MUNICH/FREISING, GERMANY/JENA, US: Wacker Biotech and XL-protein GmbH are to collaborate more intensely on the production of PASylated therapeutic proteins. WACKER and its customers will gain access to XL-protein’s PASylation platform. The PASylation technology enables the development of biopharmaceuticals with extended plasma half-lives, which require less frequent injection and thus are more patient friendly. In a recent feasibility study, PASylated human growth hormone was successfully produced in high yields using WACKER’s E. coli-based ESETEC technology.
In a feasibility study, Wacker Biotech and XL-protein tested WACKER’s patented ESETEC technology for the production of large-sized PASylated therapeutic proteins. The study showed that ESETEC produced a PASylated human growth hormone – correctly folded and fully functional – in high yields (3 to 4 g/l). Moreover, WACKER successfully used its secretion technology to develop an E. coli cell line for manufacturing the PASylated hormone. The production process is easy to implement on an industrial scale.
“Following the successful feasibility study, we are very much looking forward to intensifying our collaboration with XL-protein. More and more pharmaceutical companies are looking for efficient ways of prolonging the therapeutic effect of biologics. With this cooperation agreement with XL-protein, we can now offer our customers feasibility studies for the production of PASylated variants of their therapeutic lead candidates. Thanks to our innovative ESETEC technology, we can supply research quantities of PASylated active ingredients for pre-clinical studies within a couple of weeks,” said Dr Thomas Maier, Managing Director, Wacker Biotech GmbH.
© WOC News